Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇹🇷TR · Medicine#120500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
250 to 1.5K🎙 ~2x weekly·75 episodes·Last published 3w ago - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇹🇷100% - Active Followers
Loyal subscribers who consistently listen
200 to 1.2K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 11 epsHosts
Recent guests
Recent episodes
Hedvig Hricak and Zachary Ward on Cancer workforce—a global crisis: a Lancet Oncology Commission
May 31, 2026
23m 36s
Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
Apr 27, 2026
13m 01s
James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
Mar 30, 2026
10m 55s
Ali Landman on the European Congress of Radiology 2026
Mar 17, 2026
15m 00s
Kayleigh Bhangdia on breast cancer GBD study 2023
Mar 9, 2026
18m 23s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 5/31/26 |  Hedvig Hricak and Zachary Ward on Cancer workforce—a global crisis: a Lancet Oncology Commission✨ | cancer workforceglobal health crisis+3 | Dr Hedvig HricakDr Zachary Ward | Memorial Sloan Kettering Cancer CenterHarvard TH Chan School of Public Health+2 | New York, NY, USABoston, MA, USA | cancer workforceglobal crisis+3 | — | 23m 36s | |
| 4/27/26 | Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer✨ | quality of lifemetastatic prostate cancer+3 | Professor Fred Saad | Department of Surgery/Urology, University of MontrealThe Lancet Oncology+1 | Montreal, QC, Canada | metastatic hormone-sensitive prostate cancerquality of life+3 | — | 13m 01s | |
| 3/30/26 | James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study✨ | prostate cancertheranostics+4 | James Nagarajah | [177Lu]-PSMA-617-PSMA-617The Lancet Oncology+1 | — | prostate cancerBULLSEYE+4 | — | 10m 55s | |
| 3/17/26 | Ali Landman on the European Congress of Radiology 2026✨ | oncological imagingradiology+3 | Ali Landman | The Lancet Medical Imaging & Theranostics | Vienna | oncological imagingradiology+3 | — | 15m 00s | |
| 3/9/26 | Kayleigh Bhangdia on breast cancer GBD study 2023✨ | breast cancerepidemiological trends+4 | Kayleigh Bhangdia | GBD | 204 countries | breast cancerGBD study+5 | — | 18m 23s | |
| 2/2/26 | Dylan Graetz and Erica Kaye on qualitative research in oncology✨ | qualitative researchoncology+3 | Dr Dylan GraetzDr Erica Kaye | St Jude Children’s Research HospitalThe Power of Words: Evaluating the Role of Qualitative Methods in Cancer Research | — | qualitative researchoncology+3 | — | 42m 58s | |
| 12/29/25 | Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers✨ | cancer mortalityoccupation+3 | Dr Jesse PlascakDr Marissa Baker | The Ohio State UniversityUniversity of Washington School of Public Health | — | cancermortality rates+6 | — | 23m 47s | |
| 11/25/25 | Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3✨ | digital healthartificial intelligence+3 | Dr Andre PfobProf Peter Dubsky | Heidelberg University HospitalUniversity of Lucerne+1 | — | digital healthartificial intelligence+3 | — | 26m 34s | |
| 11/2/25 | Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission✨ | cancer carehuman dimensions+3 | Dr Gary Rodin | Lancet OncologyThe Lancet Group | — | cancerhuman crisis+4 | — | 10m 46s | |
| 10/27/25 | Matthias Preusser on the phase 2 TUXEDO-3 trial✨ | clinical trialsbrain metastases+3 | Matthias Preusser | patritumab deruxtecanMedical University of Vienna+1 | Vienna, Austria | TUXEDO-3patritumab deruxtecan+5 | — | 17m 10s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 9/29/25 | Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer✨ | bladder cancerneoadjuvant therapy+4 | Dr Andrea Necchi | Vita-Salute San Raffaele UniversitySan Raffaele Hospital+1 | — | muscle-invasive bladder cancerTAR-200+4 | — | 12m 15s | |
| 9/2/25 | Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas | Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas. In these two cohort studies, the authors analyse the expression of TERT and TERT promoter mutations in meningiomas, assess their association with patient outcomes, and discuss the potential implications fo... | 14m 22s | ||||||
| 7/28/25 | Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer | Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Dr Jinming Li, from the Department of Colorectal Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China to discuss his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00239-6?dgcid=buzzsprout_icw_podcast_July_25_lanonc Tell us what you thought ab... | 7m 36s | ||||||
| 6/11/25 | Abdalla Awidi on cancer control in the Middle East | Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's Cancer control in the Middle East Series. The Series comprises five papers from regional experts who discuss the current outlook for cancer in the Middle East and future developments. See the whole Series here: https://www.thelancet.com/series-do/cancer-control-in-middle-east?dgcid=buzz... | 8m 22s | ||||||
| 6/11/25 | ASCO 2025 Debrief | Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167 Articles discussed in this podcast episo... | 14m 45s | ||||||
| 5/28/25 | Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial) | Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial. EBIN was an open-label, randomised, controlled, phase 2 trial conducted at 37 centres in eight European countries, and aimed to investigate the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations. They discuss t... | 10m 45s | ||||||
| 4/30/25 | Richard Bryant on transperineal vs transrectal biopsy for prostate cancer | Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial. This extensive UK-based randomised controlled trial compares the use of local anaesthetic ultrasound-guided transperineal biopsy with the traditional transrectal biopsy approach for diagnosing prostate cancer. They analyse the key findings of the trial, including the detection rates of clinically significant prostate cancer, infection risk... | 18m 02s | ||||||
| 3/31/25 | Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA) | Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00034-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversati... | 7m 33s | ||||||
| 3/3/25 | Ariana Znaor on cancer surveillance in the Eastern Mediterranean region | Ariana Znaor (Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France) discusses her Review on cancer surveillance in the Eastern Mediterranean Region: a 10-year IARC-WHO EMRO collaboration. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com... | 20m 03s | ||||||
| 2/3/25 | Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials | Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-la... | 18m 03s | ||||||
| 1/2/25 | Yannick Romero on the changing landscape of national cancer control plans | Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00405-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.soci... | 24m 40s | ||||||
| 12/2/24 | M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries | Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries. Read the full Series: https://www.thelancet.com/series/cancer-care-in-saarc-countries?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode C... | 22m 15s | ||||||
| 10/30/24 | Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma | Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma. Read the full Articles here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00502-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00503-5/fulltex... | 15m 07s | ||||||
| 9/30/24 | Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination | Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations. Read the full Article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00264-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://i... | 17m 21s | ||||||
| 9/30/24 | May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics | May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics. Read the Commission: https://www.thelancet.com/commissions/radiotherapy-theranostics?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode C... | 40m 45s | ||||||
Showing 25 of 77
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.